Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingRecursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Jun 2026 · $7.7MThe company’s own SEC segment disclosure.
- License And Service$7.3M95%
- Grant$367.0K5%
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $6.5M in Q1 2026 (quarter ended Mar 31, 2026), down 56% from the same quarter a year earlier. That came with a gross margin of −93% and net loss of $118M. For the full year FY2025, revenue was $75M (+27% year on year) and net income −$645M. Its largest product in Jun 2026 was License And Service at $7.3M, 95% of the disclosed total, well ahead of Grant at 4.8%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.